PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France
Abstract
Authors
M. Massetti C. Even L. Geoffrois G. Farge L. Levy Bachelot R. Borse D. Chirovsky I. Durand-Zaleski